Inflammatory blockade prevents injury to the developing pulmonary gas exchange surface in preterm primates

Andrea Toth1,2,3,4,5, Shelby Steinmeyer1,2,3, Paranthaman Kannan1,2,3

  • 1Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Insights

Perinatal inflammation from chorioamnionitis severely damages developing fetal lungs, impairing gas exchange. Blocking inflammatory cytokines like interleukin-1β protected lung development in a primate model.

Area of Science:

  • Pulmonary Medicine
  • Developmental Biology
  • Immunology

Background:

  • Perinatal inflammatory stress, particularly chorioamnionitis, impacts fetal lung development and is linked to lifelong respiratory issues.
  • Chorioamnionitis affects 25-40% of preterm births, increasing risks for childhood pulmonary disease and infections.

Purpose of the Study:

  • To investigate the impact of experimental chorioamnionitis on primate fetal lung development.
  • To identify molecular mechanisms underlying inflammation-induced lung injury and explore therapeutic targets.

Main Methods:

  • Induced experimental chorioamnionitis in prenatal rhesus macaques using intra-amniotic lipopolysaccharide (LPS).
  • Analyzed lung structural damage and gene expression using single-cell RNA sequencing.
  • Evaluated the efficacy of blocking interleukin-1β and tumor necrosis factor-α.

Main Results:

  • LPS challenge caused significant damage to the developing alveolar gas exchange surface, disrupting alveolar type 1 pneumocytes and capillary endothelium.
  • Single-cell RNA sequencing revealed disruption of the alveolar signaling niche crucial for alveologenesis, leading to alveolar simplification.
  • Blocking inflammatory cytokines ameliorated lung injury, restored structural integrity, and modulated immune cell activation.

Conclusions:

  • Fetal inflammation profoundly disrupts lung development, causing structural damage and altering critical signaling pathways.
  • Targeting inflammatory cytokines like interleukin-1β and tumor necrosis factor-α represents a potential therapeutic strategy to mitigate developmental lung injury from chorioamnionitis.